UBS Group
EUCRU

UBS Group’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

UBS Group’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400
Closed -$3.94K – 11198
2022
Q4 		$3.94K Buy
+400
New +$3.99K ﹤0.01% 9426
2022
Q3 		– Sell
-199
Closed -$2K – 11427
2022
Q2 		$2K Sell
199
-600
-75% -$5.96K ﹤0.01% 9723
2022
Q1 		$8K Buy
799
+600
+302% +$5.95K ﹤0.01% 8752
2021
Q4 		$2K Sell
199
-1,209
-86% -$12.1K ﹤0.01% 9890
2021
Q3 		$14K Buy
1,408
+30
+2% +$300 ﹤0.01% 7620
2021
Q2 		$14K Sell
1,378
-1,300
-49% -$13.1K ﹤0.01% 7736
2021
Q1 		$27K Buy
2,678
+930
+53% +$9.91K ﹤0.01% 7113
2020
Q4 		$19K Buy
+1,748
New +$17.8K ﹤0.01% 7000

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $10.3B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return
CS
Clear Street New York $17.8B AUM 56.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return